Pierangelo Marchiolè
University of Genoa
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Pierangelo Marchiolè.
Cancer | 2004
Pierangelo Marchiolè; Annie Buenerd; Jean-Yves Scoazec; Daniel Dargent; Patrice Mathevet
The authors evaluated the accuracy of sentinel lymph node biopsy in predicting lymph node status for patients with early cervical carcinoma. In particular, the authors set out to determine the false‐negative rate associated with sentinel lymph node biopsy in this setting.
Gynecologic Oncology | 2011
Pierangelo Marchiolè; Jean Dominique Tigaud; Sergio Costantini; Serafina Mammoliti; Annie Buenerd; Eva Moran; Patrice Mathevet
OBJECTIVES The aim of the present report is to support the feasibility and the safety of a new fertility-sparing treatment in young women affected by bulky cervical cancer. METHODS Between February 2007 and October 2010, seven patients presenting large IB-IIA1 tumors (30-45 mm) were scheduled for conservative treatment. All patients underwent neoadjuvant chemotherapy (NACT) followed by laparoscopic pelvic lymphadenectomy and vaginal radical trachelectomy (VRT). RESULTS One patient presented hematological toxicity during NACT (grade 3). All patients showed complete disappearance of tumor (n=4/7) or partial response (a 50% or more decrease in total tumor size, n=3/7) to neoadjuvant treatment, and they were all treated with pelvic lymphadenectomy and VRT. Additional treatment (interstitial brachytherapy) was offered to only one woman because of a persistent parametrial tumoral lesion. After a mean follow up of 22 months (range 5-49), no relapse was observed. To date, only one woman in our study attempted to conceive and she is currently pregnant. CONCLUSIONS Neoadjuvant chemotherapy for fertility sparing treatment is an innovative approach which is potentially quite interesting for many young women affected by bulky cervical cancer. These women, i.e. those with tumors larger than 2 cm (2-5 cm), are traditionally not offered fertility sparing treatment, thus the preliminary data we report here might have a promising impact. Nevertheless, for these patients it may be suitable to use the more radical, and time-tested, conservative surgical approach to allow for a complete and conservative excision of the residual tumor after neoadjuvant treatment. Studies with a larger number of patients and adequate follow-up are required to validate this conservative approach and to define clearly the good indications for this treatment.
International Journal of Gynecological Cancer | 2012
Domenico Ferriaoli; Annie Buenerd; Pierangelo Marchiolè; Sergio Constantini; Pier Luigi Venturini; Patrice Mathevet
Introduction Cervical cancer is the second most common cancer diagnosed during pregnancy. Conservative management is possible, and different options should be discussed with patients. The main decision parameters are stage of disease, lymph node status, trimester of pregnancy and wishes of the patient. We reviewed our experience on cases of early-stage cervical cancer discovered during pregnancy and treated with different options of fertility-sparing management. Materials and Methods Between 1990 and 2010, 5 patients with early-stage cervical cancer diagnosed during pregnancy were referred to our department for fertility-sparing treatment. The mean age at diagnosis was 28.6 years (range, 26–30 years). The stages of the tumors according to the International Federation of Gynecology and Obstetrics were IA2 in 2 women and IB1 in 3 women. The histological type was squamous carcinoma in 3 cases and adenocarcinoma in 2 cases. All patients willing to preserve their fertility were treated with vaginal radical trachelectomy (VRT) and pelvic lymph nodes dissection (PLN-D). Results Three procedures were performed in the first trimester: 1 patient was treated with medical abortion and then VRT and PLN-D, 2 patients were submitted to VRT and PLN-D during the first trimester, and 1 patient’s case was complicated by spontaneous abortion. One patient was observed during the second trimester (20 weeks of gestation) and treated with VRT and PLN-D during pregnancy. Because this patient had pelvic lymph nodes positive for cancer, a cesarean delivery (CD) with radical hysterectomy and para-aortic lymph nodes dissection was performed followed by chemoradiotherapy. The last patient was evaluated during the third trimester of her pregnancy. Treatment included CD followed by VRT and PLN-D, which was delayed, to allow fetal maturity. Conclusions Diagnosis of cervical cancer can occur during pregnancy. Different options of fertility-sparing treatment can be discussed on the basis of several factors: tumor stage, gestational age, and the patient’s desire regarding fertility and pregnancy sparing.
Abdominal Imaging | 2010
Pierangelo Marchiolè; Giuseppe Cittadini; Paolo Sala; Melita Moioli; Patrice Mathevet; Enrico Capaccio; Sergio Costantini
Nowadays young women affected by early invasive uterine cervical cancer (stage IA2-IB1) may be offered a fertility-sparing treatment: the radical trachelectomy with pelvic lymph node dissection. This procedure consists in surgical removal of cervix uteri, proximal parametrial tissue, and vaginal cuff. The morphology and the functions of corpus uteri are preserved. Women candidates for trachelectomy must be closely selected. Gynecologist oncologist needs an imaging modality that can accurately value the tumoral diameter and which can demonstrate proximal extension of tumor to ensure surgical clear resection margins (especially the cranial one). Magnetic resonance imaging (MRI) is a very useful examination in pre-operative study of women affected by early cervical cancer. The aim of this study is to evaluate the role of MRI with hydrocolpos about pre- and post-operative work-up in women eligible for fertility-sparing treatment.
Gynecologic Oncology | 2007
Pierangelo Marchiolè; Mehdi Benchaib; Annie Buenerd; Emeric Lazlo; Daniel Dargent; Patrice Mathevet
Gynecologic Oncology | 2005
Pierangelo Marchiolè; Annie Buenerd; Mehdi Benchaib; Karima Nezhat; Daniel Dargent; Patrice Mathevet
Obstetrics and Gynecology Clinics of North America | 2004
Pierangelo Marchiolè; Daniel Dargent
Surgical Oncology-oxford | 2018
Pierangelo Marchiolè; Domenico Ferraioli; Eva Moran; Serafina Mammoliti; Jean Dominique Tigaud; Frédéric Beurrier; Nicolas Chopin; Patrice Mathevet
Obstetrical & Gynecological Survey | 2007
Pierangelo Marchiolè; Mehdi Benchaib; Annie Buenerd; Emeric Lazlo; Daniel Dargent; Patrice Mathevet
Annales De Pathologie | 2005
Annie Buenerd; Pierangelo Marchiolè; Lucien Frappart; Gérard Berger